- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07435389
VENTILACIÓN DURANTE EL VUELO ESPACIAL (FASE 2) (VESPA-2)
Space flights expose astronauts to medical risks, particularly respiratory risks, which are exacerbated in microgravity. Devices such as standard oxygen therapy and non-invasive ventilation (NIV) are used, but their performance in microgravity remains poorly studied. Parabolic flights allow these technologies to be evaluated in conditions similar to those encountered during space missions. In an initial study conducted in microgravity during a parabolic flight campaign, the T1 ventilator proved superior to the other devices tested on the test bench. However, its performance in healthy volunteers has not yet been evaluated. The central hypothesis of this exploratory study on healthy volunteers is that non-invasive ventilation, particularly with the CaStar UP helmet (Intersurgical), could offer superior performance to the standard oxygen mask in microgravity, thanks to better leak reduction (data from preclinical work on a test bench).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Andreia CARVALHO DE FREITAS
- Número de teléfono: 0033387553323
- Correo electrónico: projet-recherche-clinique@chr-metz-thionville.fr
Ubicaciones de estudio
-
-
-
Metz, Francia
- CHR Metz-Thionville
-
Contacto:
- Benjamin PEQUIGNOT
- Número de teléfono: 00 33 87 55 31 30
- Correo electrónico: benjamin.pequignot@chr-metz-thionville.fr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy volunteers (male or female)
- Aged 18 to 65
- Affiliated with a Social Security scheme and, for non-French residents, holders of a European Health Insurance Card (EHIC) or a Global Health Insurance Card (GHIC)
- Agreeing to participate in the study
- Agreeing to participate in the study
- Having given their informed consent in writing
- Who have undergone a medical examination similar to a standard aeronautical medical examination for private pilot fitness
Exclusion Criteria:
- Individuals who have participated in a previous biomedical research protocol
- whose exclusion period has not ended.
- Individuals in a subordinate relationship with the principal investigator or scientific director.
- Pregnant or breastfeeding women (urine pregnancy test for women of childbearing age).
- Protected adults (under guardianship, curatorship, or judicial protection)
- Flu-like symptoms, digestive symptoms (nausea, vomiting), fever.
- Altered mental state (flight-related anxiety, phobic state).
- Failure to attend the Novespace safety briefing.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ABC
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical) C. Standard oxygen therapy without EcoLite gas mask |
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). C. Standard oxygen therapy without EcoLite gas mask (Intersurgical) |
|
Experimental: ACB
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask C. Standard oxygen therapy without EcoLite gas mask B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical) |
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). C. Standard oxygen therapy without EcoLite gas mask (Intersurgical) |
|
Experimental: BAC
B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical) A . Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask C. Standard oxygen therapy without EcoLite gas mask |
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). C. Standard oxygen therapy without EcoLite gas mask (Intersurgical) |
|
Experimental: BCA
B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical) C. Standard oxygen therapy without EcoLite gas mask A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask |
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). C. Standard oxygen therapy without EcoLite gas mask (Intersurgical) |
|
Experimental: CAB
C. Standard oxygen therapy without EcoLite gas mask A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical) |
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). C. Standard oxygen therapy without EcoLite gas mask (Intersurgical) |
|
Experimental: CBA
C. Standard oxygen therapy without EcoLite gas mask B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical) A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask |
A. Non-invasive ventilation with T1 ventilator (Hamilton) and BiTrac mask (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). B. Non-invasive ventilation with T1 ventilator (Hamilton) and CaStar UP helmet (Intersurgical): specific settings (AI 10 cmH2O, PEEP 5 cmH2O, FiO2 21%, etc.). C. Standard oxygen therapy without EcoLite gas mask (Intersurgical) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Volumen tidal espiratorio
Periodo de tiempo: 24 horas
|
24 horas
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
1. Average difference between the inspiratory assistance/PEP and the pressure
Periodo de tiempo: 24 hours
|
Measured by the pneumotachograph during the last 5 respiratory cycles of the 22-second weightlessness phase |
24 hours
|
|
2. Number of double triggers and intra-cycle efforts
Periodo de tiempo: 24 hours
|
during the last 5 respiratory cycles of the 22-second weightlessness phase, as observed when reading the curves on the pneumotachograph |
24 hours
|
|
3. Average change in the "Lung volume" parameter, measured noninvasively by thoracic electrical impedance tomography (EIT)
Periodo de tiempo: 24 hours
|
During the last 5 respiratory cycles of the 22-second weightlessness phase |
24 hours
|
|
4. Self-assessment scale for dyspnea on a scale of 1 to 10
Periodo de tiempo: 24 hours
|
To be evaluated at the end of the 22-second run (Numeric Rating Scale (NRS)) 0 = no dyspnea 10 = maximum imaginable dyspnea |
24 hours
|
|
5. CO₂-inspired tidal volume and average transcutaneous CO₂ saturation (PETCO₂)
Periodo de tiempo: 24 hours
|
over the last 5 respiratory cycles during the 22-second weightlessness phase, as measured by a capnostat and by transcutaneous CO₂ measurement |
24 hours
|
|
6. Occurrence of an adverse event: PETCO2 > 50 mmHg
Periodo de tiempo: 48 hours
|
dyspnea score > 8/10, or nausea (yes/no on questioning) |
48 hours
|
|
7.The average respiratory
Periodo de tiempo: 24 hours
|
Rate over the last 5 respiratory cycles during the 22-second weightless phase. |
24 hours
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 2025-03-CHRMT
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .